CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026

CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026 Rapid oral presentation will feature final pathological and radiological outcomes and event-free survival data from the Phase 2 GDFATHER-NEO trial in muscle-invasive bladder cancer Two additional presentations to highlight ongoing Phase 2b trials evaluating visugromab in non-small cell lung cancer and hepatocellular carcinoma Munich, Germany and San Francisco, USA, October 6, 2026 – CatalYm today announced that updated clinical results from its Phase 2 GDFATHER-NEO trial will be